Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart

Fast‐acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with two added excipients (niacinamide and L‐arginine) in order to obtain accelerated absorption after subcutaneous dosing. The present study compared the pharmacokinetic/pharmacodynamic characteristics of faster aspart vs IAsp in Japanese patients with type 1 diabetes.

• Publication year

  2017

• Venue

  Journal of Diabetes Investigation

• Publication date

  2017-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jdi.12697PMID 28556616PMCID 5835461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

  2017cited by this paper
• Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart

  2017cited by this paper
• Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

  2017cited by this paper
• Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial

  2017cited by this paper
• Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

  2016cited by this paper
• Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data

  2015cited by this paper
• Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

  2015cited by this paper
• Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

  2015cited by this paper
• Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity.

  2015cited by this paper
• Dietary intake in Japanese patients with type 2 diabetes: Analysis from Japan Diabetes Complications Study

  2013cited by this paper
• The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences

  2012cited by this paper
• Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus

  2011cited by this paper
• Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring

  2011cited by this paper
• The new European Medicines Agency guideline on the investigation of bioequivalence.

  2010cited by this paper
• Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects

  2009cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine

  2008cited by this paper
• Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients.

  2008cited by this paper
• Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

  2007cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes.

  2004cited by this paper
• WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: Ethical Principles for Medical Research Involving Human Subjects

  2001cited by this paper
• Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers.

  2000cited by this paper
• SOME PROBLEMS IN INTERVAL ESTIMATION

  1954cited by this paper

• Ultrafast-acting insulin: pharmacological properties and their impact on clinical aspects

  2024cites this paper
• Comparative assessment of modern parameters of glycemic control in children with type 1 diabetes after switching to fast-acting insulin aspart using Flash Glucose Monitoring in real clinical practice

  2022cites this paper
• Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports

  2021cites this paper
• Novel approaches to pharmacological management of type 2 diabetes in Japan

  2021influential citation
• Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan.

  2021cites this paper
• The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications

  2020cites this paper
• Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial.

  2020influential citation
• Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

  2019cites this paper
• Insulin analogs: Glimpse on contemporary facts and future prospective

  2019cites this paper
• Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.

  2019cites this paper
• New faster-acting insulin Fiasp® — do we need a new meal-time insulin?

  2019cites this paper
• Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice

  2019cites this paper
• Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin

  2019cites this paper
• Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes

  2019cites this paper
• Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus

  2018cites this paper
• Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes

  2018influential citation
• Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart

  2017cites this paper
• Pharmakologische Eigenschaften des schneller wirksamen Insulins aspart (Faster-acting Insulin aspart)

  2017cites this paper